Clinigen has a portfolio of seven wholly owned Commercial Medicines where global rights were acquired from AstraZeneca, Horizon Pharmaceuticals, Medimmune, Norgine and Novartis. Our portfolio of Commercial Medicines is strengthened by more than 200 additional licensed products marketed on behalf of our industry partners around the world. We partner with a wide variety of pharmaceutical companies who are interested in streamlining their marketing and distribution or expanding their business with a single organisation in Australia, New Zealand, South Africa and South East Asia.
Through our experience and expertise with our own and partner products, we have the capability to establish and manage a dedicated team (in your company name if required) using our existing infrastructure. Our unique and flexible solution provides you with the benefits of a local presence, without committing to the cost and risk, and our substantial infrastructure and breadth of experience allows partner products to become firmly embedded within our existing range.
Whatever your requirements, you can take advantage of our successful and flexible pharmaceutical sales and marketing infrastructure. Using our extensive brand management capabilities, we work with pharmaceutical companies to ensure products reach their full potential either through acquisition or in-licensing.